TL;DR
This paper identifies lansoprazole (LNP), a common proton pump inhibitor, as a potent enhancer of amphotericin B (AmB) against the multidrug-resistant fungus Candida auris. LNP works by interfering with fungal mitochondrial respiration, specifically targeting the cytochrome bc₁ complex, leading to increased oxidative stress and restoring AmB's efficacy both in vitro and in vivo.
What Problem Does This Paper Address?
Candida auris is a rapidly emerging global health threat due to its remarkable resistance to multiple antifungal drugs, including the last-resort polyene antifungal, amphotericin B (AmB). This resistance poses a significant challenge for treating invasive candidiasis, leading to high morbidity and mortality. The existing arsenal of antifungals is insufficient, necessitating the discovery of novel therapeutic strategies. This paper addresses the urgent need for effective treatments against drug-resistant C. auris by exploring drug repurposing to find compounds that can restore the efficacy of existing antifungals.
Methods
The researchers employed a multi-pronged approach:
- Drug Library Screening: A library of 727 FDA-approved drugs was screened in vitro to identify compounds that could enhance the antifungal activity of AmB against a resistant C. auris strain.
- MIC Determination and Synergy Assays: Minimum Inhibitory Concentrations (MICs) of AmB and lansoprazole (LNP) were determined, and checkerboard assays were used to assess synergistic interactions (Fractional Inhibitory Concentration Index - EFICI).
- Time-Kill Assays: These assays evaluated the killing kinetics of the AmB/LNP combination over time.
- Proteomics (PISA Assay): Proteome Integral Solubility Alteration (PISA) was used to identify potential protein targets of LNP by analyzing changes in protein thermal stability upon drug treatment.
- RNA-Seq: Comparative RNA-sequencing was performed on C. auris treated with AmB, LNP, or the combination to understand the molecular response and identify differentially expressed genes (DEGs).
- Reactive Oxygen Species (ROS) Measurement: The generation of ROS was quantified using a fluorescent dye (H2DCFDA) in response to drug treatments.
- Fungal Respiration Assays: Experiments with S. cerevisiae mutants (rho⁰ lacking mitochondrial DNA, and sod1/sod2 mutants) were conducted to assess the role of mitochondrial respiration and oxidative stress in LNP's activity.
- Enzyme Assays: Cytochrome bc₁ enzymatic activity was measured in isolated mitochondria.
- Molecular Docking: Computational modeling was used to predict the binding poses of LNP and its metabolites to the cytochrome bc₁ complex.
- In Vivo Murine Model: The efficacy of the AmB/LNP combination was evaluated in a disseminated C. auris infection model in immunocompromised mice.
Datasets
- NIH Clinical Collections 1 and 2: A library of 727 FDA-approved drugs and clinical molecules was used for the initial drug screening.
- Fungal Isolates: 34 fungal isolates were used, including 20 clinical isolates of Candida auris representing four clades, as well as other Candida and Cryptococcus species.
- S. cerevisiae Strains: The parent strain AD1-9 and its derived mutants (rho⁰, Δsod1, Δsod2, and cytochrome b mutants) were used for mechanistic studies.
- RNA-Seq Data: Gene expression data from treated C. auris samples were generated and are available in the NCBI database (Gene Expression Omnibus [GEO]) under accession number GSE244094.
Key Insights and Ideas
- Repurposing PPIs for Antifungal Therapy: The discovery that a common proton pump inhibitor like LNP can be repurposed to combat drug-resistant fungal infections is a significant finding, offering a potential avenue for rapid clinical translation.
- Targeting Mitochondrial Respiration: The identification of cytochrome bc₁ (Complex III) as a key target for LNP is crucial. This complex is vital for fungal energy production, and its inhibition by LNP creates a vulnerability that AmB can exploit.
- Synergy Through Oxidative Stress: LNP's mechanism involves increasing oxidative stress within fungal cells, which synergizes with AmB's own ROS-generating properties. This dual attack overwhelms the fungal cell's defense mechanisms.
- Respiratory Function is Key: The experiments with S. cerevisiae mutants clearly demonstrate that an active respiratory function is essential for LNP's antifungal activity, highlighting the importance of targeting this metabolic pathway.
- Broad-Spectrum Potential: The synergistic effect of AmB/LNP was observed not only against C. auris but also against other medically important Candida and Cryptococcus species, suggesting a wider applicability.
Key Results
- Lansoprazole (LNP) was identified as a potent enhancer of AmB's antifungal activity against a multidrug-resistant C. auris strain, with 90% inhibition of growth observed in the presence of both drugs.
- The AmB/LNP combination demonstrated synergistic interactions (EFICI values between 0.25 and 0.50) against 90% of the tested C. auris isolates and other Candida and Cryptococcus species.
- LNP restored the fungicidal properties of AmB against resistant C. auris within 6 hours in a time-kill assay.
- PISA analysis identified mitochondrial cytochrome bc₁ (Complex III) as a potential target for LNP.
- RNA-Seq revealed that LNP alone had minimal effects on gene expression, while AmB and the AmB/LNP combination induced significant changes related to DNA replication, repair, and oxidative stress.
- LNP treatment led to a 29% increase in ROS levels, AmB to a 32% increase, and the combination to a significant 77% increase in ROS.
- S. cerevisiae mutants lacking superoxide dismutase (sod1 and sod2) showed significantly increased sensitivity to LNP.
- S. cerevisiae rho⁰ mutants (lacking mitochondrial DNA) were less sensitive to LNP than the parent strain, indicating the importance of respiratory function.
- Molecular docking suggested that LNP and its metabolites can bind to the Q₀ site of cytochrome bc₁.
- In a murine model of disseminated C. auris infection, the AmB/LNP combination reduced fungal burden in the kidneys by 1.7-log (98%) compared to untreated mice and by 1-log (90%) compared to AmB-treated mice.
Limitations and Future Work
- Elevated LNP Doses: The effectiveness of the AmB/LNP combination in vitro and in vivo required relatively high doses of LNP, which could be a limitation for clinical application.
- LNP Instability and Metabolites: LNP is an unstable compound with several metabolites. Further research is needed to identify the exact active metabolite responsible for the observed effects and to understand its formation process.
- Toxicological Studies: Comprehensive toxicological studies in mice are required to assess the potential adverse effects of the AmB/LNP combination.
- Future Work: The authors advocate for a comprehensive evaluation of LNP as a cytochrome bc₁ inhibitor for combating drug-resistant C. auris. They also suggest that cytochrome bc₁ inhibitors, in general, represent a promising scaffold for overcoming AmB resistance in Candida species. Further investigation into the specific metabolite(s) responsible for the enhanced antifungal activity and their precise binding mechanisms is warranted.
Summary updated